AAL-993

Research use only, not for human use.

AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.

AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on other tyrosine kinases. AAL993 also shows potent antiangiogenic and antitumor activities.(In Vitro):AAL993 suppressed HIF-1α expression through the inhibition of ERK without affecting Akt phosphorylation.(In Vivo):AAL993 (24-100 mg/kg; p.o.) inhibited both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases in B16 melanoma xenograft model. AAL993 potently inhibited VEGF-induced angiogenesis with an ED50 value of 7 mg/kg in an implant model.

AAL993 suppresses HIF-1α expression through ERK inhibition without affecting Akt phosphorylation.

AAL993 (compound 5) potently inhibits VEGF-induced angiogenesis in an implant model, with an ED50 value of 7 mg/kg.In B16 melanoma xenograft model, AAL993 (24-100 mg/kg; p.o.; daily; for 14days) inhibits both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases.

——

Angiogenesis

VEGFR

ROS|Beta Amyloid

——

——

269390-77-4

371.363

C20H16F3N3O

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (336.60 mM)

FC(F)(F)c1cccc(NC(=O)c2ccccc2NCc2ccncc2)c1

——

(-20℃)

With Ice Pack

≥ 2 years